The "Fast Money" traders give their final trades of the day.» Read More
U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.
CNBC's Jim Cramer offers some simple advice on how to deal with the Wall Street selloff.
U.S. stock index futures pointed to another steep loss on Friday, with European and Asian shares trading lower.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.
Some of Wednesday's midday movers:
Companies are making headlines before the bell Thursday.
AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.
Some of Friday's midday movers:
The "C" class has been teaching the rest of the market a lesson this year, leading the way with oversized gains.
Does the jobs report suggest the economy is kicking back into gear? Find out in the week ahead.
Some stocks are hard at work making shareholders money. And they don't show any signs of stopping.
Stocks were slightly higher Monday, with the S&P 500 pushing to a fresh high, but gains were limited as investors digested a batch of mixed earnings reports and ahead of the Federal Reserve's policy-setting meeting.
Take a look at some of Monday's midday movers:
Some of the names on the move ahead of the open.
Earnings reports from Boeing and dozens of other major companies could set the course for stocks Wednesday, as the Dow reaches for new highs.
Worried about Washington's next fiscal folly? These stocks should weather the next storm, according to two top money managers.